Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
ФГБОУ ВО «Казанский государственный медицинский университет» Минздрава России. 420012, Россия, Казань, ул. Бутлерова, д. 49
Список исп. литературыСкрыть список 1. Данилов Д.С. «Забытый» исследователями перициазин и его значение для современной клинической практики. Психиатрия и психофармакотерапия. 2015; 17 (1): 31–7. / Danilov D.S. Periciazine «forgotten» by researchers and its significance for modern clinical practice. Psychiatry and Psichopharmacotherapy. 2015; 17 (1): 31–7. [in Russian] 2. Данилов Д.С. К вопросу о медикаментозном лечении расстройств личности (открытое письмо профессору В.Д.Менделевичу). Психиатрия и психофармакотерапия. 2017; 19 (1): 57–61. / Danilov D.S. Talking about drug treatment of personality disorders (open letter to Professor V.D.Mendelevich). Psychiatry and Psychopharmacotherapy. 2017; 19 (1): 57–61. [in Russian] 3. Менделевич В.Д. Поведенческие расстройства или девиации поведения. Психиатрия и психофармакотерапия. 2000; 2 (6): 166–8. / Mendelevich V.D. Povedencheskie rasstroistva ili deviatsii povedeniia. Psychiatry and Psychopharmacotherapy. 2000; 2 (6): 166–8. [in Russian] 4. Менделевич В.Д. Казус художника-акциониста Петра Павленского: психопатология или современное искусство? Неврол. вестн. 2016; 1: 4–16. / Mendelevich V.D. Kazus khudozhnika-aktsionista Petra Pavlenskogo: psikhopatologiia ili sovremennoe iskusstvo? Nevrol. vestn. 2016; 1: 4–16. [in Russian] 5. Менделевич В.Д. Классификация психических расстройств vs. систематика поведенческих девиаций: медикализация как тренд. Обозрение психиатрии и мед. психологии. 2016; 1: 10–6. / Mendelevich V.D. Klassifikatsiia psikhicheskikh rasstroistv vs. sistematika povedencheskikh deviatsii: medikalizatsiia kak trend. Obozrenie psikhiatrii i med. psikhologii. 2016; 1: 10–6. [in Russian] 6. Менделевич В.Д. От Ганнушкина до Павленского: классификация расстройств и реальная жизнь. Неврол. вестн. 2016; 4: 58–60. / Mendelevich V.D. Ot Gannushkina do Pavlenskogo: klassifikatsiia rasstroistv i real'naia zhizn'. Nevrol. vestn. 2016; 4: 58–60. [in Russian] 7. Симуткин Г.Г., Яковлева А.Л., Бохан Н.А. Проблема коморбидности аффективных расстройств и расстройств личности. Соц. и клин. психиатрия. 2014; 2: 92–8. / Simutkin G.G., Iakovleva A.L., Bokhan N.A. Problema komorbidnosti affektivnykh rasstroistv i rasstroistv lichnosti. Sots. i klin. psikhiatriia. 2014; 2: 92–8. [in Russian] 8. Снедков Е.В. Личность в призме психиатрического менталитета (комментарий к статье В.Д.Менделевича). Часть 1. Неврол. вестн. 2016; 4: 47–57. / Snedkov E.V. Lichnost' v prizme psikhiatricheskogo mentaliteta (kommentarii k stat'e V.D.Mendelevicha). Chast' 1. Nevrol. vestn. 2016; 4: 47–57. [in Russian] 9. Федеральные клинические рекомендации по диагностике и лечению расстройств личности. РОП, 2014. http://psychiatr.ru/news/175 / Federal'nye klinicheskie rekomendatsii po diagnostike i lecheniiu rasstroistv lichnosti. ROP, 2014. http://psychiatr.ru/news/175 [in Russian] 10. APA. Practice guidelines for the treatment of patients with borderline personality disorder. Washington, DC, USA: APA, 2001. 11. Barich N. Borderline Personality Disorder: A Mental Disorder or the Medicalization of Social Undesirability? WUPJ 2014; 2 (1). 12. Bateman A, Fonagy P. Randomized controlled trial of outpatient mentalization-based treatment versus structured clinical management for borderline personality disorder. Am J Psychiatry 2009; 166: 1355–64. 13. Belli H, Ural C. Bordeline personality disorder: bipolarity, mood stabilizers and atypical antipsychotics in treatment. J Clin Med Res 2012; 4 (5): 301–8. 14. Blum N, John D, Fohl BP et al. Systems Training for Emotional Predictability and Problem Solving (STEPPS) for Outpatients with Personality Disorder: A Randomized Controlled Trial and One-Year Follow-Up. Am J Psychiatry 2008; 165: 468–78. 15. Borderline personality disorder: Treatment and Management, National Clinical Practice Guideline Number 78. The British Psychological Society and The Royal College of Psychiatrists, 2009. http:// www.rcpch.ac.uk/sites/default/files/asset_library/Research/Clinical%20Effectiveness/Endorsed%20guide.... pdf 16. Bourne J. From bad character to BPD: the medicalization of "personality disorder". In De-Medicalizing Misery Psychiatry, Psychology and thе Human Condition Edited by Mark Rapley. London, 2011; p. 66–85. 17. Brune M. Bordeline personality disorder. Why "fast and furious". Evolution, Medicine, and Public Health. 2016; p. 52–66. DOI:10.1093/emph/eow002 18. Clinical Practice Guideline for the Management of Borderline Personality Disorder. Commonwealth of Australia, 2012. 19. Conrad P. The Medicalization of Society. Baltimore, 2007. 20. Crawford MJ. Are mood stabilizers helpful in treatment of borderline personality disorder? BMJ 2014; 349. DOI: https://doi.org/10.1136/ bmj.g5378 21. Francois D, Roth SD, Klingman D. Efficacy of pharmacotherapy for borderline personality disorder: a review of available randomized controlled trials. Psychiatr Ann 2015; 45 (8):431–7. 22. Ingenhoven T, Lafay P, Rinne T et al. Effectiveness of pharmacotherapy for severe personality disorders: meta-analyses of randomized controlled trials. J Clin Psychiatry 2010; 71: 14–25. 23. Knappich M, Horz-Sagstetter S, Schwerthoffer D et al. Pharmacotherapy in the treatment of patients with borderline personality dosirder: results of a survey among psychiatrists in private practices. Int Clin Psychopharmacol 2014; 29: 224–8. 24. Lieb K, Vollm B, Rucker G et al. Pharmacotherapy for borderline personality disorder: Cochrane systematic review of randomized trials. Br J Psychiatry 2010; 196: 4–12. DOI: 10.1192/ bjp.bp.108.062984 25. Linehan MM, Comtois KA, Murray AM et al. Two-Year Randomized Controlled Trial and Follow-up of Dialectical Behavior Therapy vs. Therapy by Experts for Suicidal Behaviors and Borderline Personality Disorder. Arch Gen Psychiatry 2006; 63: 757–66. 26. Loy JH. Atypical antipsychotics for disruptive behavior disorders in children and youths. Cochrane Database Syst Rev 2012; 9: CD008559. DOI: 10.1002/14651858.CD008559.pub2 27. Paolini E, Mezzetti FA, Pierri F, Moretti P. Pharmacological treatment of borderline personality disorder: a retrospective observational study at inpatient unit in Italy. Int J Psychiatry Clin Pract 2017; 21 (1): 75–9. DOI: 10.1080/13651501.2016.1235202 28. Pies R. Should DSM-V Designate "Internet Addiction" a Mental Disorder? Psychiatry (Edgemont) 2009; 6 (2): 31–7. 29. Reimer M. Moral Disorder In the DSM-IV?: The Cluster B Personality Disorders. Philos Psychiatr Psychol 2013; 20 (3): 203–15. 10.1353/ppp.2013.0034 30. Rippol LH. Psychopharmacological treatment of borderline personality disorder. Dialogues Clin Neurosci 2013; 15 (2): 213–24. 31. Schneider J. The Medicalization of Deviance: From Badness to Sickness. Handbook on Sociology of Deviance, Wiley. 2015; p. 1–33. 32. Schulz SC. Bordeline personality disorder: research and clinical progress to me made. Aust J Psychiatry Behav Sci 2017; 4 (1): 1058. 33. Shafti SS, Kaviani H. A comparative study on olanzapine and aripiprazole for symptom management with borderline personality disorder. Bull Clin Psychopharmacol 2015; 25 (1): 38–43. 34. Stoffers JM, Vollm BA, Rucker G et al. Psychological therapies for people with borderline personality disorder. Cochrane Database Syst Rev 2012; 8: CD005652. DOI: 10.1002/14651858.CD0056 52.pub2 35. Stoffers JM, Vollm BA, Rucker G et al. Pharmacological intervention for borderline personality disorder. Cochrane Database Syst Rev 2014; 6: CD005653. DOI: 10.1002/14651858.CD00 5653.pub2 36. Tyrer P, Silk KR. A comparison of UK and US guideline for drug treatment in borderline personality disorder. Int Rev Psychiatry 2010; 23: 388–94.